Symptomatic delayed-acting drugs (SYSADOA): new applications
https://doi.org/10.14412/1996-7012-2022-2-99-106
Abstract
The review systematizes modern data indicating effective pain control and a significant improvement in the functional activity of patients suffering from osteoarthritis (OA) using pharmaceutical substances of chondroitin sulfate (CS) and glucosamine (GA). The effect of a combination of CS and GA on subclinical inflammation (low-grade inflammation) in the joints, slowing down the progression of OA, reducing cardiovascular risk, metabolic disorders, etc. are discussed. There are promising reports of a possible decrease in overall mortality and mortality from cardiovascular diseases during long-term therapy with symptomatic delayed-acting drugs (SYSADOA). A wide range of pleiotropic effects of CS and HA allows us to classify these drugs as geroprotectors and recommend their use not only in OA, but also in various comorbid conditions.
Keywords
About the Authors
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Elena Aleksandrovna Taskina
34A, Kashirskoe shosse, Moscow 115522, Russia
2/1, Barrikadnaya street, building 1, Moscow 125993, Russia
E. A. Taskina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522, Russia
L. I. Alekseeva
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522, Russia
2/1, Barrikadnaya street, building 1, Moscow 125993, Russia
N. G. Kashevarova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522, Russia
References
1. Zhang Z, Huang C, Jiang Q, et al. Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition). Ann Transl Med. 2020 Oct;8(19):1213. doi: 10.21037/atm-20-4665.
2. Kolasinski SL, Neogi T, Hochberg MC. American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020 Feb;72(2):220-33. doi: 10.1002/art.41142. Epub 2020 Jan 6.
3. Safiri S, Kolahi AA, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020 Jun;79(6):819-28. doi: 10.1136/annrheumdis-2019-216515. Epub 2020 May 12.
4. Quicke JG, Conaghan PG, Corp N, Peat G. Osteoarthritis year in review 2021: epidemiology & therapy. Osteoarthritis Cartilage. 2022 Feb;30(2):196-206. doi: 10.1016/j.joca.2021.10.003. Epub 2021 Oct 22.
5. Turkiewicz A, Petersson IF, Bjцrk J, et al. Current and future impact of osteoarthritis on health care: a populationbased study with projections to year 2032. Osteoarthritis Cartilage. 2014 Nov;22(11):1826-32. doi: 10.1016/j.joca.2014.07.015. Epub 2014 Jul 30.
6. Costa D, Cruz EB, Silva C, et al. Factors Associated With Clinical and Radiographic Severity in People With Osteoarthritis: A Cross-Sectional Population-Based Study. Front Med (Lausanne). 2021 Nov 15;8:773417. doi: 10.3389/fmed.2021.773417.eCollection 2021.
7. Lynch M, Bucknall M, Jagger C, Wilkie R. Healthy working life expectancy at age 50 for people with and without osteoarthritis in local and national English populations. Sci Rep. 2022 Feb 14;12(1):2408. doi: 10.1038/s41598-022-06490-3.
8. https://www.hse.gov.uk/statistics/overall/hssh1920.pdf.
9. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020 Nov 28;396(10264):1711-12. doi: 10.1016/S0140-6736(20)32230-3. Epub 2020 Nov 4.
10. Martynov AI, Naumov AV, Vertkin AL, et al. Management of osteoarthritis patients with comorbidity in general medical practice: expert opinion based on evidence-based medicine. Lechashchii vrach. 2015;(4):39-46. (In Russ.).
11. Lila AM, Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis as an interdisciplinary problem: treatment algorithm for physicians and general practitioners. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(5):68-75. (In Russ.). doi: 10.14412/1996-7012- 2021-5-68-75.
12. Constantino de Campos G, Mundi R, Whittington C, et al. Osteoarthritis, mobilityrelated comorbidities and mortality: an overview of meta-analyses. Ther Adv Musculoskelet Dis. 2020 Dec 25;12:1759720X20981219. doi: 10.1177/ 1759720X20981219. eCollection 2020.
13. Rayson A, Boudiffa M, Naveed M, et al. Geroprotectors and Skeletal Health: Beyond the Headlines. Front Cell Dev Biol. 2022 Feb 9;10:682045. doi: 10.3389/fcell.2022.682045. eCollection 2022.
14. DeMartino GN. Introduction to the Thematic Minireview Series: Autophagy. J Biol Chem. 2018 Apr 13;293(15):5384-5. doi: 10.1074/jbc.TM118.002429. Epub 2018 Feb 21.
15. Weimer S, Priebs J, Kuhlow D, et al. D-glucosamine Supplementation Extends Life Span of Nematodes and of Ageing Mice. Nat Commun. 2014 Apr 8;5:3563. doi: 10.1038/ncomms4563.
16. Denzel Ms, Storm NJ, Gutschmidt A, et al. Hexosamine Pathway Metabolites Enhance Protein Quality Control and Prolong Life. Cell. 2014 Mar 13;156(6):1167-78. doi: 10.1016/j.cell.2014.01.061.
17. Ma H, Li X, Zhou T, et al. Glucosamine Use, Inflammation, and Genetic Susceptibility, and Incidence of Type 2 Diabetes: A Prospective Study in UK Biobank. Diabetes Care. 2020 Apr;43(4):719-25. doi: 10.2337/dc19-1836. Epub 2020 Jan 27.
18. Veronese N, Demurtas J, Smith L, et al. Glucosamine sulphate: an umbrella review of health outcomes; on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and MetaAnalyses and Arthritis. Ther Adv Musculoskelet Dis. 2020 Dec 26;12:1759720X20975927. doi: 10.1177/1759720X20975927. eCollection 2020.
19. Kantor ED, Lampe JW, Vaughan TL, et al. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol. 2012 Dec 1;176(11):1002-13. doi: 10.1093/aje/kws186. Epub 2012 Nov 8.
20. Navarro SL, White E, Kantor ED, et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015 Feb 26;10(2):e0117534. doi: 10.1371/journal.pone.0117534.
21. Sibbritt D, Adams J, Lui CW, et al. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One 2012;7:e41540.10.1371/journal.pone.004154.
22. King DE, Xiang J. Glucosamine/Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med. Nov-Dec 2020; 33(6):842-7. doi: 10.3122/ jabfm.2020.06.200110.
23. Ma H, Li X, Sun D, et al. Association of Habitual Glucosamine Use with Risk of Cardiovascular Disease: Prospective Study in UK Biobank. BMJ. 2019 May 14;365:l1628. doi: 10.1136/bmj.l1628.
24. Bell GA, Kantor ED, Lampe JW, et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012 Aug; 27(8):593-603. doi: 10.1007/s10654-012-9714-6.
25. Mazzucchelli R, Rodriguez-Martнn S, Garcia-Vadillo A, et al. Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study. PLoS One. 2021 Jul 12;16(7):e0253932. doi: 10.1371/journal.pone.0253932. eCollection 2021.
26. Masola V, Zaza G, Onisto M, et al. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014 Jun;33(3):243-54.
27. Herrero-Beaumont G, Marcos ME, Sa’nchez-Pernaute O, et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis: Chondroitin sulphate in atherosclerosis. Br J Pharmacol. 2008 Jun;154(4):843-51. doi: 10.1038/bjp.2008.113. Epub 2008 Apr 21.
28. Largo R, Martiґnez-Calatrava MJ, Sa’nchez-Pernaute O, et al. Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. Am J Physiol Heart Circ Physiol. 2009 Jul; 297(1):H268-76. doi: 10.1152/ajpheart.00142.2009. Epub 2009 May 1.
29. Xu CX, Jin H, Chung YS, et al. Chondroitin sulfate extracted from the Styela clava tunic suppresses TNF-alpha-induced expression of inflammatory factors, VCAM-1 and iNOS by blocking Akt/NF-kappaB signal in JB6 cells. Cancer Lett. 2008 Jun 8;264(1):93-100. doi: 10.1016/j.canlet.2008.01.022. Epub 2008 Mar 4.
30. Chou MM, Vergnolle N, McDougall JJ, et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood). 2005 Apr;230(4):255-62. doi: 10.1177/153537020523000405.
31. Sakai S, Sugawara T, Kishi T, et al. Effect of glucosamine and related compounds on the degranulation of mast cells and ear swelling induced by dinitrofluorobenzene in mice. Life Sci. 2010 Feb 27;86(9-10):337-43. doi: 10.1016/j.lfs.2010.01.001. Epub 2010 Jan 20.
32. Melgar-Lesmes P, Sa’nchez-Herrero A, Lozano-Juan F, et al. Chondroitin Sulphate Attenuates Atherosclerosis in ApoE Knockout Mice Involving Cellular Regulation of the Inflammatory Response. Thromb Haemost. 2018 Jul;118(7):1329-39. doi: 10.1055/s-0038-1657753. Epub 2018 Jun 6.
33. Li ZH, Gao X, Chung VC, et al. Associations of Regular Glucosamine Use with All-Cause and Cause-specific Mortality: a Large Prospective Cohort Study. Ann Rheum Dis. 2020 Jun;79(6):829-36. doi: 10.1136/annrheumdis-2020-217176.
34. Lila AM, Alekseeva LI, Taskina EA. Modern approaches to the treatment of osteoarthritis based on the updated international recommendations. Russkii meditsinskii zhurnal. Meditsinskoe obozrenie. 2019;3(11-2):48-52. (In Russ.).
35. Veronese N, Demurtas J, Smith L, et al; European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020 Dec 26;12:1759720X20975927. doi: 10.1177/1759720X20975927. eCollection 2020.
36. Reginster JY, Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res. 2021 Jan;33(1):37-47. doi: 10.1007/s40520-020-01643-8. Epub 2020 Jul 7.
37. Rubio-Terres C, Grupo del estudio VECTRA. An economic evaluation of chondroitin sulfate and non-steroidal anti-infammatory drugs for the treatment of osteoarthritis. Data from the VECTRA study. Reumatol Clin. Jul-Aug 2010;6(4):187-95. doi: 10.1016/j.reuma.2009.12.009. Epub 2010 Jun 24.
38. Yang W, Sun C, He SQ, et al. The Efficacy and Safety of DiseaseModifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis – a Systematic Review and Network Meta-Analysis. J Gen Intern Med. 2021 Jul;36(7):2085-93. doi: 10.1007/ s11606-021-06755-z.
39. Owens S, Wagner P, Vangsness C. Recent Advances in Glucosamine and Chondroitin Supplementation. J Knee Surg. 2004 Oct; 17(4):185-93. doi: 10.1055/s-0030-1248220.
40. Zhu X, Sang L, Wu D, et al. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018 Jul 6;13(1):170. doi: 10.1186/s13018-018-0871-5.
41. Meng Z, Liu J, Zhou N. Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis. Arch Orthop Trauma Surg. 2022 Jan 13. doi: 10.1007/s00402-021-04326-9. Online ahead of print.
42. Alekseeva LI, Chichasova NV, Mendel' OI. Results of the use of the drug artra ® in gonarthrosis. Nauchno-prakticheskaya revmatologiya. 2004;42(2):10. (In Russ.).
43. Alekseeva LI, Chichasova NV, Mendel' OI. Rational choice of basic therapy for osteoarthritis. Results of an open randomized multicenter study of the drug ARTRA® in Russia. Russkii meditsinskii zhurnal. 2005;13(24):637-1640. (In Russ.).
44. Vertkin AL, Naumov AV. Deforming osteoarthritis: a strategy for managing patients with somatic pathology. Russkii meditsinskii zhurnal. 2007;15(4):319-24. (In Russ.).
45. Mendel' OI, Naumov AV, Alekseeva LI, et al. Osteoarthritis as a risk factor for cardiovascular disasters. Russkii meditsinskii zhurnal. 2010;18(6):400-4. (In Russ.).
46. Rodionova SS, Es'kin NA, Matveeva NYu, Morozova NS. Rational choice of treatment of the initial stages of gonarthrosis in patients suffering from systemic osteoporosis. Vestnik travmatologii i ortopedii im. N.N. Priorova. 2014; (2):52-6. (In Russ.).
47. Rodionova SS, Es'kin NA. Combination of chondroitin sulfate and glucosamine (arthra drug) for pain relief and reduction of consumption of nonsteroidal anti-inflammatory drugs in patients with stages I-II osteoarthritis of the knee joints. Khirurgiya. Zhurnal im. N.I. Pirogova. 2016;(1):67-72. (In Russ.).
48. Alekseeva LI, Alekseev VV, Barinov AN, et al. New approaches to the treatment of nonspecific pain in the lower back. Nauchnoprakticheskaya revmatologiya. 2016;54(1):16-20. (In Russ.).
Review
For citations:
Lila AM, Taskina EA, Alekseeva LI, Kashevarova NG. Symptomatic delayed-acting drugs (SYSADOA): new applications. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(2):99-106. (In Russ.) https://doi.org/10.14412/1996-7012-2022-2-99-106
Views:
3624
Email this article 